forecast

First drug generates $400 million in launch year

Argenx's first approved drug generated about $400 million in its first year of launch and is growing strongly, supporting a projection of $7 to $8 billion in revenue from the first four programs within five to seven years.

forecastpending

Speaker

Julia

Evidence Quote

“you can see how it can become $7 billion, $8 billion opportunity within next five, seven years”

Source

Argenx: Changing Lives with Llamas— Business Breakdowns
Created: 11/17/2026, 3:39:21 AM

Your notes

Loading notes...